Published in Proc Natl Acad Sci U S A on June 08, 1999
Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev (2003) 2.06
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol (2005) 1.68
Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol (2000) 1.53
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47
Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin Vaccine Immunol (2009) 1.46
Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol (2010) 1.26
Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol (2001) 1.21
Effective vaccination against long-term gammaherpesvirus latency. J Virol (2003) 1.19
Herpes simplex viruses: is a vaccine tenable? J Clin Invest (2002) 1.18
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis (2009) 1.17
Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. J Virol (2000) 1.16
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One (2011) 1.10
Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine (2008) 1.08
Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol (2002) 1.06
Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis (2011) 1.02
Herpes simplex virus type 1 glycoprotein E mediates retrograde spread from epithelial cells to neurites. J Virol (2009) 1.01
Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology (2007) 1.00
A herpesvirus encoded deubiquitinase is a novel neuroinvasive determinant. PLoS Pathog (2009) 0.99
Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency. J Virol (2004) 0.98
Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology (2007) 0.94
Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol (2011) 0.93
Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS One (2010) 0.92
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol (2012) 0.92
Mechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation. J Virol (2003) 0.91
Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. PLoS One (2012) 0.91
Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol (2006) 0.90
High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS One (2013) 0.88
Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine (2012) 0.87
The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines (2012) 0.85
High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol (2008) 0.85
The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol (2004) 0.84
Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. PLoS One (2015) 0.81
Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine (2010) 0.81
Directed antigen delivery as a vaccine strategy for an intracellular bacterial pathogen. Proc Natl Acad Sci U S A (2006) 0.81
Active immunization in the United States: developments over the past decade. Clin Microbiol Rev (2001) 0.80
Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology (2016) 0.80
Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach. BMC Microbiol (2013) 0.78
Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol (2004) 0.77
Towards an effective genital herpes vaccine: past lessons and future prospects. Future Virol (2007) 0.76
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. J Virol (2015) 0.75
Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. J Virol (1988) 5.11
A method for identifying the viral genes required for herpesvirus DNA replication. Proc Natl Acad Sci U S A (1986) 4.61
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J Virol (1992) 3.56
The genome sequence of herpes simplex virus type 2. J Virol (1998) 3.39
Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol (1995) 3.18
Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J Virol (1990) 3.05
Progress in the development of an HIV-1 vaccine. Science (1998) 2.77
The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J Virol (1997) 2.55
Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J Virol (1989) 2.35
A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine (1994) 2.22
Mutations in the major DNA-binding protein gene of herpes simplex virus type 1 result in increased levels of viral gene expression. J Virol (1983) 1.98
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis (1988) 1.92
Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology (1998) 1.86
Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis (1997) 1.60
Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein. J Virol (1983) 1.51
Latent infection can be established with drastically restricted transcription and replication of the HSV-1 genome. Virology (1993) 1.48
A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis (1997) 1.44
Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol (1994) 1.42
The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex. J Virol (1992) 1.36
Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol (1992) 1.26
Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 1.25
Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology (1997) 1.23
Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol (1994) 1.11
Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J Gen Virol (1990) 1.06
Neuron-specific restriction of a herpes simplex virus recombinant maps to the UL5 gene. J Virol (1994) 1.06
Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis (1998) 1.04
Recombinant Salmonella vectors in vaccine development. Dev Biol Stand (1994) 1.03
In vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector. J Gen Virol (1996) 0.91
Molecular genetics of herpes simplex virus. II. Mapping of the major viral glycoproteins and of the genetic loci specifying the social behavior of infected cells. J Virol (1979) 8.05
Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol (1989) 5.77
Stimulation of expression of a herpes simplex virus DNA-binding protein by two viral functions. Mol Cell Biol (1985) 5.76
The intranuclear location of a herpes simplex virus DNA-binding protein is determined by the status of viral DNA replication. Cell (1984) 4.90
A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J Virol (1989) 4.85
Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion. Proc Natl Acad Sci U S A (1978) 4.31
Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells. Science (1988) 4.16
Separate pathways of maturation of the major structural proteins of vesicular stomatitis virus. J Virol (1977) 4.03
Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27. J Virol (1990) 3.63
Maturation of viral proteins in cells infected with temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1977) 3.30
Transcriptional control of herpesvirus gene expression: gene functions required for positive and negative regulation. Proc Natl Acad Sci U S A (1986) 3.28
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A (1989) 3.26
Stages in the nuclear association of the herpes simplex virus transcriptional activator protein ICP4. J Virol (1987) 3.24
Localization of two cellular forms of the vesicular stomatitis viral glycoprotein. J Virol (1977) 3.20
Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein. Cell (1988) 3.13
Gene-specific transactivation by herpes simplex virus type 1 alpha protein ICP27. J Virol (1988) 3.08
Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus. J Virol (1982) 2.99
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Molecular genetics of herpes simplex virus. VI. Characterization of a temperature-sensitive mutant defective in the expression of all early viral gene products. J Virol (1981) 2.52
Dual regulation of the yeast CDC28-p40 protein kinase complex: cell cycle, pheromone, and nutrient limitation effects. Cell (1987) 2.43
Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J Virol (1989) 2.35
A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J Virol (1997) 2.35
Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis (1998) 2.16
Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol (2000) 2.16
Inactivation of essential division genes, ftsA, ftsZ, suppresses mutations at sfiB, a locus mediating division inhibition during the SOS response in E. coli. EMBO J (1984) 2.16
Satisfactory cross cultural equivalence of the Dutch WOMAC in patients with hip osteoarthritis waiting for arthroplasty. Ann Rheum Dis (2004) 2.15
The development of the immune system during pregnancy and early life. Allergy (2000) 2.04
Evidence for a novel regulatory pathway for herpes simplex virus gene expression in trigeminal ganglion neurons. J Virol (1993) 2.01
Herpes simplex virus alpha protein ICP27 can inhibit or augment viral gene transactivation. Virology (1989) 1.99
Characterization of the major mRNAs transcribed from the genes for glycoprotein B and DNA-binding protein ICP8 of herpes simplex virus type 1. J Virol (1984) 1.99
Mutations in the major DNA-binding protein gene of herpes simplex virus type 1 result in increased levels of viral gene expression. J Virol (1983) 1.98
Molecular genetics of herpes simplex virus. III. Fine mapping of a genetic locus determining resistance to phosphonoacetate by two methods of marker transfer. J Virol (1979) 1.97
Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology (1998) 1.86
Thermolabile in vivo DNA-binding activity associated with a protein encoded by mutants of herpes simplex virus type 1. J Virol (1983) 1.86
Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model. Virology (2000) 1.82
On the structure, functional equivalence, and replication of the four arrangements of herpes simplex virus DNA. Cold Spring Harb Symp Quant Biol (1979) 1.80
Potential role for herpes simplex virus ICP8 DNA replication protein in stimulation of late gene expression. J Virol (1991) 1.79
Identification of a herpes simplex virus function that represses late gene expression from parental viral genomes. J Virol (1985) 1.79
Functional order of assembly of herpes simplex virus DNA replication proteins into prereplicative site structures. J Virol (1996) 1.78
Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis (1998) 1.78
A mutant herpesvirus protein leads to a block in nuclear localization of other viral proteins. Mol Cell Biol (1986) 1.75
Characterization of two conformational forms of the major DNA-binding protein encoded by herpes simplex virus 1. J Virol (1982) 1.75
Molecular genetics of herpes simplex virus: the terminal a sequences of the L and S components are obligatorily identical and constitute a part of a structural gene mapping predominantly in the S component. Proc Natl Acad Sci U S A (1979) 1.73
Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. J Biol Chem (2001) 1.72
Rapid accumulation of phosphatidylinositol 4,5-bisphosphate and inositol 1,4,5-trisphosphate correlates with calcium mobilization in salt-stressed arabidopsis. Plant Physiol (2001) 1.69
Preexisting nuclear architecture defines the intranuclear location of herpesvirus DNA replication structures. J Virol (1994) 1.65
The physical maps for sequencing human chromosomes 1, 6, 9, 10, 13, 20 and X. Nature (2001) 1.63
Acceptability and feasibility of urine screening for Chlamydia and gonorrhea in community organizations: perspectives from Denver and St Louis. Am J Public Health (2000) 1.62
Herpes simplex ICP27 mutant viruses exhibit reduced expression of specific DNA replication genes. J Virol (1996) 1.61
Assembly of herpes simplex virus replication proteins at two distinct intranuclear sites. Virology (1997) 1.60
The acidic amino-terminal region of herpes simplex virus type 1 alpha protein ICP27 is required for an essential lytic function. J Virol (1993) 1.59
Herpes simplex virus alpha protein ICP27 possesses separable positive and negative regulatory activities. J Virol (1989) 1.59
Polycomblike PHD fingers mediate conserved interaction with enhancer of zeste protein. J Biol Chem (2001) 1.57
Correct intranuclear localization of herpes simplex virus DNA polymerase requires the viral ICP8 DNA-binding protein. J Virol (1991) 1.55
Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol (2000) 1.53
Accumulation of viral transcripts and DNA during establishment of latency by herpes simplex virus. J Virol (1998) 1.52
Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein. J Virol (1983) 1.51
Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. Br J Anaesth (2012) 1.51
Body size, dose of hemodialysis, and mortality. Am J Kidney Dis (2000) 1.48
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47
Comparison of the intranuclear distributions of herpes simplex virus proteins involved in various viral functions. Virology (1998) 1.46
Genetic identification of a portion of the herpes simplex virus ICP8 protein required for DNA-binding. Virology (1988) 1.45
An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J (1997) 1.43
Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol (1994) 1.42
Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation. Virology (2000) 1.42
Racial difference in incidence of ABO hemolytic disease. Am J Public Health (1976) 1.41
Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987). Cytogenet Cell Genet (1987) 1.40
Isolation and characterization of renin-expressing cell lines from transgenic mice containing a renin-promoter viral oncogene fusion construct. J Biol Chem (1990) 1.39
Use of alternate splice sites in granule-bound starch synthase mRNA from low-amylose rice varieties. Plant Mol Biol (1998) 1.38
An immunoassay for the study of DNA-binding activities of herpes simplex virus protein ICP8. J Virol (1985) 1.37
Restricted expression of herpes simplex virus lytic genes during establishment of latent infection by thymidine kinase-negative mutant viruses. J Virol (1990) 1.35
Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci U S A (1999) 1.35
Nuclear localization of herpesvirus proteins: potential role for the cellular framework. Mol Cell Biol (1983) 1.34
Herpes simplex virus infection blocks events in the G1 phase of the cell cycle. Virology (2000) 1.31
Distal protein sequences can affect the function of a nuclear localization signal. Mol Cell Biol (1992) 1.31
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
An Abd-B class HOX.PBX recognition sequence is required for expression from the mouse Ren-1c gene. J Biol Chem (2001) 1.29
Induction of DNA-protein crosslinks in human cells by ultraviolet and visible radiations: action spectrum. Photochem Photobiol (1985) 1.28
Membrane assembly: synthesis and intracellular processing of the vesicular stomatitis viral glycoprotein. J Supramol Struct (1977) 1.27
Mutagenesis and cytotoxicity in human epithelial cells by far- and near-ultraviolet radiations: action spectra. Radiat Res (1987) 1.27
Herpes simplex virus 1 ICP27 is required for transcription of two viral late (gamma 2) genes in infected cells. Virology (2001) 1.27
Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology (1996) 1.26
Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol (1992) 1.26
Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology (1997) 1.23
Association between the herpes simplex virus major DNA-binding protein and alkaline nuclease. J Virol (1992) 1.23
Prenatal origins of allergic disease. J Allergy Clin Immunol (2000) 1.23
Role of proximal promoter elements in regulation of renin gene transcription. J Biol Chem (1996) 1.22
Blepharophimosis and its association with female infertility. Br J Ophthalmol (1984) 1.22
Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J Comp Neurol (1994) 1.21
Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res (1990) 1.19
Reduced morbidity for elderly patients with a hip fracture after implementation of a perioperative evidence-based clinical pathway. Qual Saf Health Care (2006) 1.17
Viral replication is required for induction of ocular immunopathology by herpes simplex virus. J Virol (1996) 1.17
Role of protein kinase A and the serine-rich region of herpes simplex virus type 1 ICP4 in viral replication. J Virol (1996) 1.17
Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol (2001) 1.16
Bioactive transforming growth factor-beta in the lungs of extremely low birthweight neonates predicts the need for home oxygen supplementation. Biol Neonate (2000) 1.16
Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension (1997) 1.16
Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia. J Virol (1993) 1.13
Mechanism of virus-induced Ig subclass shifts. J Immunol (1994) 1.12
Mapping of the transcriptional initiation site of the herpes simplex virus type 1 ICP8 gene in infected and transfected cells. J Virol (1987) 1.12